Top Page
Oxford Nanopore Technologies PLC
(LSE:ONT)
Oxford Nanopore Technologies PLC (ONT) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford Nanopore Technologies PLC Business Overview & Revenue Model
Oxford Nanopore Technologies PLC Earnings Call Summary
Oxford Nanopore Technologies PLC Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 223.90M | 183.19M | 169.67M | 198.60M | 133.66M |
| Gross Profit | 131.30M | 105.39M | 90.48M | 123.81M | 73.19M |
| EBITDA | -105.50M | -93.09M | -105.71M | -49.67M | -140.34M |
| Net Income | -145.20M | -146.19M | -154.51M | -91.03M | -167.61M |
Balance Sheet | |||||
| Total Assets | 622.50M | 742.05M | 777.06M | 823.89M | 841.87M |
| Cash, Cash Equivalents and Short-Term Investments | 255.30M | 338.37M | 270.05M | 476.19M | 618.47M |
| Total Debt | 41.50M | 45.96M | 41.66M | 34.10M | 24.80M |
| Total Liabilities | 159.20M | 155.71M | 133.21M | 130.33M | 137.89M |
| Stockholders Equity | 463.30M | 586.34M | 643.85M | 693.56M | 703.98M |
Cash Flow | |||||
| Free Cash Flow | -66.30M | -123.83M | -164.59M | -91.62M | -84.64M |
| Operating Cash Flow | -62.80M | -109.89M | -137.30M | -49.39M | -53.83M |
| Investing Cash Flow | 48.50M | 15.03M | -61.79M | -65.79M | -161.99M |
| Financing Cash Flow | -2.10M | 73.58M | 64.73M | -13.71M | 622.90M |
Oxford Nanopore Technologies PLC Technical Analysis
Oxford Nanopore Technologies PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £75.76M | 9.98 | 64.40% | 8.33% | -3.61% | -6.35% | |
52 Neutral | £22.25M | -5.90 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £1.09B | -7.48 | -26.01% | ― | 22.03% | 20.01% | |
45 Neutral | £10.73M | -0.26 | -407.49% | ― | 72.17% | 79.03% | |
42 Neutral | £271.19M | ― | ― | ― | ― | ― | |
41 Neutral | £83.62M | -5.44 | -209.34% | ― | 198.49% | -26.66% |
Oxford Nanopore Technologies PLC Corporate Events
Oxford Nanopore Technologies plans to engage investors at two major March conferences, the Barclays Annual Global Healthcare Conference in Miami and the Berenberg UK Corporate Conference in Hertfordshire. The company will host analyst-led fireside chats and investor meetings, with a live and on-demand webcast of the Barclays session available via its investor relations site, underscoring its efforts to broaden institutional engagement and visibility in global healthcare and UK equity markets.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has granted its chief executive officer, Francis Van Parys, conditional awards over 583,791 ordinary shares under its 2021 Long Term Incentive Plan. The awards are intended to compensate him for incentive awards forfeited on leaving his previous employer and are structured to mirror the original vesting schedule without an additional holding period.
The share awards were calculated using a reference price of £1.2944 per share, based on the average closing middle-market price over the five business days before the grant date. The package underscores the company’s use of equity-based incentives to attract and retain senior leadership, aligning executive compensation with shareholder interests through multi-year vesting across several dates out to 2029.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc, a life sciences company specialising in nanopore-based DNA and RNA sequencing platforms for research and applied markets, has disclosed a share transaction involving its chair. The company’s technology is used worldwide in genomics, clinical research and other sectors that require rapid, scalable sequencing solutions.
The company reported that chair Duncan Tatton-Brown purchased 87,000 ordinary shares on 2 March 2026 at £1.1550 per share on the London Stock Exchange. The transaction, valued at £100,485 in total, was announced under UK Market Abuse Regulation requirements, signaling increased personal financial commitment from a key board member and providing transparency for investors and other market participants.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £159.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has issued 190,389 new ordinary shares following the exercise of options under its share option plans and the operation of certain remuneration schemes, with these shares admitted to the FCA’s Official List and trading on the London Stock Exchange under its existing block listing facility. Following this issuance, the company’s total issued share capital stands at 967,098,047 ordinary shares with no treasury shares, establishing the updated total voting rights figure that shareholders must use to assess and report any notifiable interests or changes in holdings under UK disclosure rules.
The block listing facility still allows Oxford Nanopore to admit a further 5,427,157 ordinary shares, indicating continued capacity to satisfy future option exercises or share-based remuneration without requiring a separate full listing process. The updated share and voting rights data provides clarity and compliance with the FCA’s transparency regime, ensuring investors and other stakeholders have an accurate denominator for calculating their ownership stakes and disclosure obligations.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £159.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore reported 2025 revenue of £223.9 million, up 24.2% on a constant-currency basis, with gross margin improvement and a reduced adjusted EBITDA loss, supported by strong demand across all regions and customer segments. Growth was particularly strong in Clinical, BioPharma and Applied Industrial markets and in the PromethION range, while the company maintained a solid cash position despite restructuring costs aimed at sharpening strategic focus and progressing towards profitability.
Operationally, the group advanced major research and population-scale sequencing projects, deepened its presence in infectious disease through collaborations with Cepheid and bioMérieux, and registered its first IVD product, GridION Dx, reinforcing its move into regulated clinical markets. Management also expanded manufacturing capacity, pursued IP litigation to protect its technology, and announced a leadership transition with industry veteran Francis Van Parys taking over as CEO, as it guides investors to low‑20s percentage revenue growth in 2026 and reiterates targets for EBITDA breakeven in 2027 and positive cash flow in 2028.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £159.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has secured a key admission in its Australian patent dispute, with MGI Australia conceding that its Cyclone SEQ WT02 instrument infringes four of Oxford Nanopore’s Australian patents. The Federal Court has confirmed that liability for infringement is not contested, with a trial scheduled for 2027 to examine MGI’s remaining defences and consider the question of additional or enhanced damages.
In a parallel move, Oxford Nanopore has launched legal action in the UK High Court against several MGI and BGI entities, alleging trade secrets infringement, breach of confidence and breach of contract. The twin legal tracks underscore the company’s strategy of vigorously protecting the intellectual property behind its sensing platform, which it views as central to long-term value creation and competitive positioning in the global genomics and molecular analysis market.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £159.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc announced that non-executive director John O’Higgins has been nominated to become non-executive chair of Technip Energies NV, subject to shareholder approval at Technip Energies’ annual general meeting in May 2026. The prospective appointment underscores the external recognition of Oxford Nanopore’s board-level expertise and may further strengthen the company’s strategic networks and influence across adjacent technology and industrial sectors.
The move does not alter Oxford Nanopore’s core operational focus on expanding adoption of its nanopore sequencing technologies for real-time DNA and RNA analysis worldwide. However, O’Higgins’ potential new role at a major Paris-listed engineering and technology company could enhance cross-industry dialogue, potentially benefiting Oxford Nanopore’s longer-term positioning and stakeholder relationships, particularly in areas where advanced analytics intersect with industrial and environmental applications.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £159.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has reported a routine share transaction under its Share Incentive Plan, involving Chief Financial Officer and director Nick Keher. The plan allows employees to buy partnership shares out of gross salary, reinforcing long-term alignment between management, staff, and shareholders.
On 12 February 2026, Keher acquired 105 partnership shares at £1.43 each via the plan’s trustee and received a matching award of 105 newly issued ordinary shares at no cost. The disclosure, made under UK Market Abuse Regulation, reflects ongoing use of equity-based incentives but represents a small, largely administrative change to the company’s overall capital structure.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £159.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has issued 850,633 new ordinary shares following the exercise of employee share options and the operation of its remuneration schemes for the month ended 31 January 2026. The newly issued shares have been admitted to the FCA’s Official List and to trading on the London Stock Exchange under the company’s existing block listing facility, leaving capacity to admit a further 5,617,546 shares. As a result, the company’s issued share capital now stands at 966,907,658 ordinary shares, all carrying voting rights, a figure that investors can use to calculate disclosure thresholds under UK transparency rules.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £250.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has reported a routine share transaction under its Share Incentive Plan involving Chief Financial Officer and director Nick Keher. Keher purchased 100 partnership shares at £1.50 each using gross salary, and, in line with the plan’s terms, the company issued a further 100 matching shares to be held by the plan trustee on his behalf. The disclosure, made under UK Market Abuse Regulation requirements, underscores ongoing use of equity-based incentives to align senior management with shareholder interests.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies reported a strong trading performance for 2025, expecting full-year revenue of approximately £223–224 million, up about 22% on a reported basis and 24% at constant currency, slightly ahead of its guidance. Growth was broad-based across regions, with all major geographies delivering more than 20% constant currency revenue increases, and across end markets, led by around 60% growth in Clinical revenue, 30% in BioPharma and 27% in Applied Industrial, while Research revenue rose about 15% despite funding pressures. Product demand was driven particularly by the PromethION range, which grew more than 40% year-on-year, underscoring continued adoption of its high-throughput platforms. The group also highlighted progress on its path to profitability and ended 2025 with roughly £302 million in cash and liquid investments, ahead of consensus expectations, providing a solid capital base to support its strategy. Oxford Nanopore plans to publish its preliminary results for the year ended 31 December 2025 on 2 March 2026, accompanied by a management presentation and Q&A.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £140.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc will engage with investors at two major January events, the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and the dbAccess UK & Ireland Conference in London, featuring a presentation, Q&A and investor meetings. The planned outreach, including a publicly accessible webcast of the J.P. Morgan session, underscores the company’s efforts to raise its visibility in the healthcare and life sciences investment community and to reinforce its positioning as a key player in real-time genomic and molecular analysis technologies.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has issued 190,696 new ordinary shares following the exercise of employee share options and the operation of certain remuneration schemes, with the new shares admitted to the FCA’s Official List and to trading on the London Stock Exchange’s main market under the company’s existing block listing facility. Following this allotment, Oxford Nanopore’s issued share capital stands at 966,057,025 ordinary shares with no treasury shares held, establishing the updated total voting rights figure that shareholders must use to assess disclosure thresholds under UK transparency rules and leaving headroom for the admission of a further 6,468,179 shares under the current block listing.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC announced a transaction involving the Share Incentive Plan (SIP) for its Chief Financial Officer, Nick Keher. On December 12, 2025, 118 ordinary shares were purchased on behalf of Keher, with an equal number of matching shares issued under the SIP. This move aligns with the company’s obligations under the UK Market Abuse Regulation, potentially impacting stakeholder confidence and reinforcing the company’s commitment to employee investment.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies has engaged with major shareholders following its 2025 AGM to understand their concerns regarding a specific resolution. The company is committed to refining its strategic planning to maximize long-term value, and has appointed Francis Van Parys as CEO to lead the next phase of growth and enhance its commercial strategy.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £128.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc has announced the appointment of Francis Van Parys as the new Chief Executive Officer, effective March 2, 2026. Van Parys, who brings extensive experience from leading roles at Radiometer, Cytiva, and GE Healthcare, will succeed Gordon Sanghera, the company’s founding CEO. This leadership transition is expected to drive the next phase of growth for Oxford Nanopore, leveraging Van Parys’ expertise in scaling innovation-driven businesses. The company anticipates continued expansion and innovation under his leadership, aiming to enhance operational execution and deliver value to stakeholders.
The most recent analyst rating on (GB:ONT) stock is a Hold with a £128.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.